BR112013025222A2 - composição farmacêutica anti-hipertensiva - Google Patents

composição farmacêutica anti-hipertensiva

Info

Publication number
BR112013025222A2
BR112013025222A2 BR112013025222A BR112013025222A BR112013025222A2 BR 112013025222 A2 BR112013025222 A2 BR 112013025222A2 BR 112013025222 A BR112013025222 A BR 112013025222A BR 112013025222 A BR112013025222 A BR 112013025222A BR 112013025222 A2 BR112013025222 A2 BR 112013025222A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
antihypertensive pharmaceutical
hydrate
antihypertensive
pharmaceutically acceptable
Prior art date
Application number
BR112013025222A
Other languages
English (en)
Other versions
BR112013025222B1 (pt
BR112013025222B8 (pt
Inventor
In Jin Jang
Je Hak Kim
Ji Han Kim
Joo Han Lee
Joo Youn Cho
Kyung Sang Yu
Kyung Wan Nam
Sang Goo Shin
Seo Hyun Yoon
Seung Ho Kim
So Jeong Yi
Soo Heui Paik
Tae Eun Kim
Yong Ha Chi
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47006840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025222(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of BR112013025222A2 publication Critical patent/BR112013025222A2/pt
Publication of BR112013025222B1 publication Critical patent/BR112013025222B1/pt
Publication of BR112013025222B8 publication Critical patent/BR112013025222B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição farmacêutica anti-hipertensiva a presente invenção fornece uma composição farmacêutica anti-hipertensiva contendo fimasaetan, um sal farmaceuticamente aceitável do mesmo, um solvagto do mesmo ou um hidrato do mesmo como um bloqueador dos recptores da angiotensina ii; e anlodipino, um isômero da mesma, um sal farmaceuticamente aceitável do mesmo, um solvato do mesmo ou um hidrato do mesmo como um bloqueador dos canais de cálcio.
BR112013025222A 2011-04-12 2011-08-08 composição farmacêutica anti-hipertensiva e uso da mesma BR112013025222B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0033856 2011-04-12
KR20110033856 2011-04-12
PCT/KR2011/005754 WO2012141385A1 (en) 2011-04-12 2011-08-08 Antihypertensive pharmaceutical composition

Publications (3)

Publication Number Publication Date
BR112013025222A2 true BR112013025222A2 (pt) 2016-12-27
BR112013025222B1 BR112013025222B1 (pt) 2020-03-17
BR112013025222B8 BR112013025222B8 (pt) 2020-05-05

Family

ID=47006840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025222A BR112013025222B8 (pt) 2011-04-12 2011-08-08 composição farmacêutica anti-hipertensiva e uso da mesma

Country Status (20)

Country Link
US (1) US8765776B2 (pt)
JP (1) JP5782178B2 (pt)
AU (1) AU2011365756B2 (pt)
BR (1) BR112013025222B8 (pt)
CA (1) CA2832758C (pt)
CL (1) CL2013002905A1 (pt)
CO (1) CO6821940A2 (pt)
CR (1) CR20130526A (pt)
EA (1) EA024096B1 (pt)
EC (1) ECSP13012962A (pt)
GT (1) GT201300241A (pt)
MA (1) MA35107B1 (pt)
MX (1) MX341450B (pt)
MY (1) MY160432A (pt)
NI (1) NI201300106A (pt)
PE (1) PE20141049A1 (pt)
SG (1) SG194162A1 (pt)
UA (1) UA110244C2 (pt)
WO (1) WO2012141385A1 (pt)
ZA (1) ZA201307593B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110244C2 (en) 2011-04-12 2015-12-10 Boryung Pharm Antihypertensive pharmaceutical composition
KR101490329B1 (ko) * 2012-10-12 2015-02-04 보령제약 주식회사 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
KR20140096514A (ko) * 2013-01-28 2014-08-06 보령제약 주식회사 암 예방 또는 치료용 조성물
JP6068765B2 (ja) * 2013-03-14 2017-01-25 ボリュン ファーマスーティカル カンパニー リミテッド 薬学的複合製剤
KR20150041223A (ko) * 2013-10-04 2015-04-16 보령제약 주식회사 피마살탄을 포함하는 허혈성 뇌질환 예방 또는 치료용 약학적 조성물
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN112704667A (zh) * 2021-02-24 2021-04-27 施慧达药业集团(吉林)有限公司 含苯磺酸左氨氯地平水合物的组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0733366B1 (en) 1988-01-07 1998-04-01 E.I. Du Pont De Nemours And Company Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics
KR100300566B1 (ko) 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도
KR19990081093A (ko) * 1998-04-25 1999-11-15 조생현 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
TR200100062T2 (tr) 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
KR100617953B1 (ko) 2000-03-23 2006-08-30 보령제약 주식회사 피리미디논 화합물 및 이의 염의 제조방법
JP4268871B2 (ja) * 2001-09-21 2009-05-27 ボリョン ファーマシューティカル カンパニー リミテッド ピリミジノン化合物及びその薬剤として許容される塩の製造方法
KR100521980B1 (ko) 2002-10-10 2005-10-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
JP5148296B2 (ja) * 2005-06-27 2013-02-20 第一三共株式会社 アンジオテンシンｉｉ受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR20100048137A (ko) 2008-10-30 2010-05-11 현대약품 주식회사 혈압 강하용 약학 조성물
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
UA110244C2 (en) 2011-04-12 2015-12-10 Boryung Pharm Antihypertensive pharmaceutical composition

Also Published As

Publication number Publication date
EA201370219A1 (ru) 2014-02-28
BR112013025222B1 (pt) 2020-03-17
AU2011365756B2 (en) 2015-07-30
MY160432A (en) 2017-03-15
SG194162A1 (en) 2013-11-29
UA110244C2 (en) 2015-12-10
CL2013002905A1 (es) 2014-04-11
US20120264772A1 (en) 2012-10-18
US8765776B2 (en) 2014-07-01
CO6821940A2 (es) 2013-12-31
CA2832758A1 (en) 2012-10-18
WO2012141385A1 (en) 2012-10-18
MX2013011879A (es) 2014-03-31
EA024096B1 (ru) 2016-08-31
ZA201307593B (en) 2015-04-29
AU2011365756A1 (en) 2013-10-31
GT201300241A (es) 2015-08-13
NI201300106A (es) 2014-05-05
JP5782178B2 (ja) 2015-09-24
CR20130526A (es) 2014-03-11
JP2014510785A (ja) 2014-05-01
BR112013025222B8 (pt) 2020-05-05
ECSP13012962A (es) 2013-11-29
MA35107B1 (fr) 2014-05-02
CA2832758C (en) 2015-12-15
PE20141049A1 (es) 2014-09-05
MX341450B (es) 2016-08-19

Similar Documents

Publication Publication Date Title
BR112013025222A2 (pt) composição farmacêutica anti-hipertensiva
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
TN2014000063A1 (en) Kinase inhibitor polymorphs
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX358499B (es) Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
BR112014025041B8 (pt) Composição farmacêutica
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
BR112015019587A2 (pt) combinações compreendendo compostos maba e corticosteroides
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
CY1119525T1 (el) Συνθεση 3-(5-αμινο-2-μεθυλ-4-οξοκιναζολιν-3(4η)-υλ)πιπε-ριδινο-2,6-διονης
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
EA201390603A1 (ru) Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
EA201591480A1 (ru) Способы лечения дискинезии и сопутствующих расстройств
EA201400444A1 (ru) Производные 2-оксопиперидинила
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2567 DE 17/03/2020 QUANTO AO ENDERECO.